Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;7(4):579-591.
doi: 10.1007/s41669-023-00416-z. Epub 2023 May 13.

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study

Ryan Pulleyblank  1 , Nikolaj Birk Larsen  2
Affiliations

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study

Ryan Pulleyblank et al. Pharmacoecon Open. 2023 Jul.

Abstract

Objective: The aim was to evaluate the cost-effectiveness of oral and subcutaneous semaglutide versus other oral glucose-lowering drugs (i.e., empagliflozin, canagliflozin, and sitagliptin) for the management of type 2 diabetes (T2D) in Denmark using clinically relevant treatment intensification rules.

Methods: A Markov-type cohort model for evaluating the cost-effectiveness of treatment pathways for T2D was used to produce cost-effectiveness estimates based on four head-to-head trials. Evidence from PIONEER 2 and 3 trials was used to evaluate the cost-effectiveness of oral semaglutide vs. empagliflozin and sitagliptin. Evidence from SUSTAIN 2 and 8 trials was used to evaluate the cost-effectiveness of subcutaneous semaglutide vs. sitagliptin and canagliflozin. Base case analyses used trial product estimands of treatment efficacy to avoid the confounding effects of rescue medication use during trials. Deterministic scenario analyses and probabilistic sensitivity analyses were conducted to assess robustness of cost-effectiveness estimates.

Results: Semaglutide-based treatment regimens were consistently associated with higher lifetime diabetes treatment costs, lower costs of complications, and higher lifetime accumulated QALYs. The PIONEER 2 analysis estimated the cost-effectiveness of oral semaglutide vs. empagliflozin was DKK 150,618/QALY (€20,189). The PIONEER 3 analysis estimated the cost-effectiveness of oral semaglutide vs. sitagliptin was DKK 95,093/QALY (€12,746). The SUSTAIN 2 analysis estimated the cost-effectiveness of subcutaneous semaglutide vs. sitagliptin was DKK 79,982/QALY (€10,721). The SUSTAIN 8 analysis estimated the cost-effectiveness of subcutaneous semaglutide vs. canagliflozin was DKK 167,664/QALY (€22,474).

Conclusions: Daily oral and weekly subcutaneous semaglutide are likely to both increase cost and health benefits, but are likely to do so under commonly considered cost-effectiveness thresholds.

Trial registrations: Clinicaltrials.gov: NCT02863328 (PIONEER 2; registered August 11, 2016); NCT02607865 (PIONEER 3; registered November 18, 2015); NCT01930188 (SUSTAIN 2; registered August 28, 2013); NCT03136484 (SUSTAIN 8; registered May 2, 2017).

PubMed Disclaimer

Conflict of interest statement

RP and NL are employed by NHTA, which provides consulting services for commercial life-sciences enterprises, including funding from Novo Nordisk.

Figures

Fig. 1
Fig. 1
Cost-effectiveness planes and cost-effectiveness acceptability curves (payer perspective). S.C. subcutaneous, QALY quality-adjusted life-years.
Fig. 2
Fig. 2
Trial ICERs vs. Semaglutide discount. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years
See this image and copyright information in PMC

References

    1. Han H, et al. Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2022;45(2):319–329. doi: 10.2337/dc21-1512. - DOI - PubMed
    1. Faselis C, et al. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):117–124. doi: 10.2174/1570161117666190502103733. - DOI - PubMed
    1. Viigimaa M, et al. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):110–116. doi: 10.2174/1570161117666190405165151. - DOI - PubMed
    1. Magliano DJ, et al. Young-onset type 2 diabetes mellitus—implications for morbidity and mortality. Nat Rev Endocrinol. 2020;16(6):321–331. doi: 10.1038/s41574-020-0334-z. - DOI - PubMed
    1. Owens-Gary MD, et al. The importance of addressing depression and diabetes distress in adults with type 2 diabetes. J Gen Intern Med. 2019;34(2):320–324. doi: 10.1007/s11606-018-4705-2. - DOI - PMC - PubMed

Associated data

LinkOut - more resources